Clinical trial NCT05945498: Evaluation of ТВ/Flu-05Е Vaccine for the Prevention of Tuberculosis Infection in BCG-vaccinated Volunteers Aged 18-50 Years
Official title: Randomized, Double-blind, Placebo-controlled Phase 1 Trial of ТВ/Flu-05Е Intranasal Vector Vaccine for the Prevention of Tuberculosis Infection in BCG-vaccinated Volunteers Aged 18-50
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Tuberculosis Infection
Keywords: Tuberculosis infection
Vaccine
BCG boost
Influenza vector
Lead sponsor: Research Institute of Influenza, Russia
Sponsor class: OTHER
First posted: 2023-07-14
Enrollment: 51
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The aim of the study is to investigate safety, reactogenicity and immunogenicity of the TB/Flu-05E single-dose intranasal vaccine for the prevention of Tuberculosis infection in BCG-vaccinated Volunteers aged 18-50 years.

Detailed description: Study include 51 participants in two cohorts. At the first stage, 15 volunteers (Cohort 1), randomized in a 2:1 ratio (10 people in the vaccine group and 5 people in the placebo group) will be included in the study. At the second stage, the following 36 people (Cohort 2) will be included in the study, which will be randomly distributed (randomization) in a ratio of 2: 1 for the vaccine preparation (24 people) and placebo (12 people). Duration of the study for each participant is about 4 months (no more than 122 days).

Eligibility criteria: Inclusion Criteria:

1. Healthy BCG-vaccinated men and women aged 18 to 50 years
2. Availability of signed informed consent
3. Diagnosed "healthy" according to the data of standard clinical, laboratory and instrumental examination methods, with the absence of clinically significant changes. Participants with chronic conditions that do not require special treatment, such as diabetes mellitus, hypertension, or heart disease, are eligible to participate in this study if the investigator considers the participant's condition to be medically stable
4. The ability and willingness to make entries in the diary of self-observation, as well as to carry out all the visits foreseen in the study for control medical observation
5. Consent to use effective contraceptive methods throughout their participation in the study.
6. Body weight ≥ 50 kg
7. HI antibody titers ≤1:20 to influenza A/H1N1pdm09
8. Negative test for alcohol in exhaled air
9. Consent to use effective contraceptive methods throughout their participation in the study
10. Values of the complete blood count and biochemical blood analysis (during the screening) within 0.9\*reference range lower limit and 1,1 \* reference range upper limit
11. Negative tests for HIV, hepatitis B, hepatitis C, and syphilis

Exclusion Criteria:

1. Participation in another clinical study within three months prior to the start of the current study; planning to participate in another study during the current study period
2. Clinical, radiological or laboratory signs of active or previously transferred tuberculosis of any localization.
3. Passage in the past or at the present time of examination in anti-tuberculosis medical institutions
4. Existence in the past or present of contact with patients with any form of tuberculosis (at home, at work, in the circle of friends and acquaintances)
5. Tuberculous infection confirmed by the TB-FERON IGRA laboratory test
6. Immunization with BCG within six months prior to enrollment in the current study
7. Contact with COVID-19 patients within 14 days prior to the start of the clinical study
8. Positive rapid test result for SARS-CoV-2 antigen
9. Immunization with any other non-study vaccine product within three weeks prior to enrollment in the current study, or refusal to postpone such until the end of the three-week period after completion of the current study
10. Regular use of nasal irrigation therapy during the last six months prior to enrollment in the current study or episodic use of the above method of treatment in the two weeks prior to the screening
11. History of frequent nosebleeds (\>5) during the year prior to the current study
12. Clinically significant anatomic pathology or the presence of surgical intervention in the sinus area, paranasal sinuses, or traumatic injuries of the nose within a month before screening
13. Symptoms of acute respiratory disease, including fever, or other acute illness at the time of screening or within two weeks prior to screening
14. Treatment with immunoglobulins or other blood derived medications in the three months prior to screening or planning such treatment during the period of participation in the current study; donation of blood/plasma (450 ml or more) less than 2 months prior to screening
15. The presence or suspicion of the presence of various immunosuppressive or immunodeficiency conditions or continuous use (the drug was prescribed for more than 14 days without a break) of immunosuppressive drugs, immunomodulators for 6 months before the screening (for corticosteroids, ≥0.5 mg/kg per day of prednisone or other corticosteroid equivalent; topical and inhaled steroids).
16. History of bronchial asthma
17. Hypersensitivity and the presence of severe allergic reactions, including Quincke's edema, anaphylactic shock after the previous administration of any vaccine
18. History of wheezing after previous immunization with live influenza vaccine
19. Other adverse events after immunization (fever above 40°C, syncope, non-febrile convulsions, anaphylaxis) when there is a minimal likelihood that they are associated with a previous administration of any vaccine
20. Suspicion of hypersensitivity to any component of the study vaccine, including egg protein
21. Seasonal (in spring or autumn) increased sensitivity to the effects of natural factors
22. Acute or chronic clinically significant lung, cardiovascular, hepatic, endocrine, neurological, or psychiatric disorders, or impaired renal function identified by history, physical examination, or clinical laboratory findings that, in the opinion of the investigator, may influence the outcome of the study
23. History of leukemia or any other malignant diseases of the blood or solid malignant neoplasms of other organs
24. History of thrombocytopenic purpura or bleeding disorders
25. History of convulsions
26. The presence or suspicion of the presence of various immunosuppressive or immunodeficiency conditions, including HIV infection
27. Tuberculosis or residual changes after tuberculosis according to the anamnesis and / or available medical documentation
28. Chronic alcohol dependence or chronic use of illicit drugs, drug abuse
29. Claustrophobia and social phobia according to history and / or available medical records
30. For women of reproductive age - lactation, pregnancy or suspected pregnancy, early postpartum period
31. Premenopausal women (last menstrual period \<1 year prior to signing informed consent) who are not surgically sterile and women who are of reproductive potential but do not use or plan to use valid birth control throughout the study and do not agree to perform a urine pregnancy test while participating in the study
32. Military personnel undergoing military service on conscription
33. Persons in custody in pre-trial detention centers and serving sentences in places of deprivation of liberty
34. Special diet (eg, vegetarian, vegan, salt-restricted) or lifestyle (night work, extreme physical activity)
35. Any condition that, in the opinion of the investigator, may increase the risk to the health of a volunteer participating in the study or affect the results of the study

Primary outcomes:
measure: Number of participants with local and systemic adverse events (AEs) and serious adverse events (SAEs)
timeFrame: Throughout the study, average of 4 months
Secondary outcomes:
measure: Concentration of cytokines in nasal secrets after vaccination
timeFrame: Days 1, 2, 3
measure: Level of mucosal IgA antibody in nasal secret/saliva
timeFrame: Days 1, 21
measure: Level of TB antigen-specific cytokine producing T-cells
timeFrame: Days 1, 7, 21
measure: Level of influenza specific cytokine producing T-cells
timeFrame: Days 1, 7, 21
measure: Level of TB antigen-specific cytokine release in whole blood assay
timeFrame: Days 1, 7, 21
measure: Level of А/H1N1pdm09 influenza specific cytokine release in whole blood assay
timeFrame: Days 1, 7, 21
measure: Level of TB antigen-specific IgG antibody
timeFrame: Days 1, 21
measure: Influenza specific local antibody immune response
timeFrame: Days 1, 21
measure: Influenza specific systemic antibody immune response
timeFrame: Days 1, 21
Other outcomes:
Locations:
city: Saint Petersburg
country: Russian Federation
facility: Smorodintsev Research Institute of Influenza
Study officials:
References: